JAKAFI
NDC 50881-025, ruxolitinib, tablet, from Incyte Corporation.
- Product NDC
- 50881-025
- Status
- Listed
- Labeler
- Incyte Corporation
- Dosage form
- TABLET
- Route
- ORAL
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application
- NDA202192
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/50881-025 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- RUXOLITINIB25 mg/1
Pharmacologic classes
Janus Kinase Inhibitor [EPC]; Janus Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 50881-025-60 | 50881002560 | 60 TABLET in 1 BOTTLE, PLASTIC (50881-025-60) |
Linked data
RxNorm, label and prices
RxNorm concepts
Related lookups
FDA label sections
GET /v1/drugs/labels/f1c82580-87ae-11e0-bc84-0002a5d5c51b
Use it
Look up 50881-025 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/50881-025 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 50881-025. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.